*Madam ---* Recent Royal College of Radiologists\' treatment guidelines for lung cancer during the COVID-19 pandemic \[[@bib1]\] motivated us to share the findings of our recent audit of accelerated hypofractionated concurrent chemoradiotherapy in inoperable stage III non-small cell lung cancer (NSCLC; SOCCAR regimen): 55 Gy in 20 fractions over 26 days with concomitant chemotherapy (cisplatin and vinorelbine) \[[@bib2]\].

All 163 stage III A/B NSCLC patients who received this regimen between January 2012 and December 2016 were included. Data were censored on 31 March 2018. Kaplan--Meier analysis was used to estimate 1-, 2- and 3-year survival rates and the median overall survival. The median follow-up was 38 months.

Our data allay concerns over the delivery of chemotherapy concurrently with hypofractionated radiotherapy and confirm the efficacy of the SOCCAR regimen. Only 3% of our patients did not complete the planned radiotherapy and 76% received both cycles of concurrent chemotherapy. There were no 30- or 90-day treatment-related deaths. The median overall survival was 31.2 months; 1-, 2- and 3-year survival rates were 75, 56 and 45%, respectively.

To our knowledge this is the largest series of patients treated with this regimen; a number similar to the control arm of RTOG 0617. The median survival of 31.2 months in this real-life population outperforms all the 2 Gy per fraction arms delivering 60--66 Gy in recently published trial populations prior to the use of adjuvant immunotherapy. The median survival in the control arm of RTOG 0617 was 28.7 months \[[@bib3]\]. The median survival was 25 and 26.8 months in the arms of the PROCLAIM trial \[[@bib4]\] and 29.1 months in the control arm of PACIFIC \[[@bib5]\].

Our findings validate a smaller series that reported a median survival of 43 months in patients treated with the SOCCAR regimen \[[@bib6]\] and support the use of moderately hypofractionated radiotherapy with concomitant chemotherapy in patients with stage III NSCLC.
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